[Intra-tympanic gentamicin in the treatment of Ménière's disease: preliminary results ]

C Marín Garrido1, J Fraile Rodrigo, M J Naya Gálvez

  • 1Hospital Universitario Miguel Servet de Zaragoza. crismaring@yahoo.com

Insights

Intratympanic gentamicin offers a safe and effective treatment for Ménière's disease when medical management fails. This study shows good vertigo control in 66.6% of patients, with low risk and few complications.

Area of Science:

  • Otolaryngology
  • Neurology
  • Pharmacology

Context:

  • Ménière's disease often requires aggressive treatment beyond medication for severe vertigo.
  • Intratympanic gentamicin is explored as an alternative to more invasive procedures.

Purpose:

  • To evaluate the efficacy and safety of intratympanic gentamicin in Ménière's disease patients unresponsive to medical treatment.
  • To assess outcomes in vertigo control, hearing, and functional levels.

Summary:

  • A prospective study of 24 Ménière's disease patients showed intratympanic gentamicin achieved good vertigo control (Types A and B) in 66.6% (16/24).
  • Acceptable results (Type C) were seen in 12.5% (3/24), while 20.83% (5/24) required further surgical intervention.
  • The treatment demonstrated a low risk profile with scarce complications.

Impact:

  • Intratympanic gentamicin presents a viable, less aggressive therapeutic option for refractory Ménière's disease.
  • This approach can improve patient quality of life by reducing vertigo frequency and severity.